Search clinical trials for: EGFR C797S mutation

Total 4292 results

AstraZeneca

Completed

Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutation in Lung Cancer Patients (PANORAMRETRO)

Carcinoma, Non-Small-Cell Lung

Argentina, Colombia, Uruguay, Chile
AstraZeneca

Completed

ARTEMIS DIANE T790M (An Amino Acid Substitution at Position 790 in EGFR, From a Threonine (T) to a Methionine (M)) Mutation at Hospital Laboratories in Comparison With Central Laboratory

Locally Advanced or Metastatic EGFR(+) NSCLC Patients

China
Universität Duisburg-Essen

Terminated

Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE) (Trans-MARBLE)

Non-small-cell Lung Cancer With Somatic EGFR Mutations
The University of Hong Kong

Unknown

Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors

NSCLC Stage IV | EGFR Activating Mutation | NSCLC Stage IIIB

Hong Kong
Cancer Institute and Hospital, Chinese Academy...

Unknown

TKI Followed by Thoracic Radiotherapy for Stage IV EGFR Mutant NSCLC

Non-Small Cell Lung Cancer Metastatic

China
Incyte Corporation

Withdrawn

Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating Mutations

Solid Tumors and Hematologic Malignancy | NSCLC (Non-small Cell Lung Carcinoma)

United States
University of Washington
National Cancer Institute (NCI)

Terminated

Nivolumab and Plinabulin in Treating Patients With Stage IIIB-IV, Recurrent, or Metastatic Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | EGFR Activating Mutation | Stage IV Non-Small Cell Lung Cancer AJCC v7 | ALK Gene Translocation | Stage IIIB Non-Small Cell Lung Cancer AJCC v7 | ROS1 Gene Translocation

United States
Hospital Erasto Gaertner
AstraZeneca

Completed

Frequency of EGFR and KRAS Mutations and Clinical-prognostic Correlation in Brazilian Lung Cancer Patients

Lung Neoplasms | KRAS Gene Mutation | EGFR Gene Mutation

Brazil
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Non-Small-Cell Lung Cancer

Japan
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations (SOLAR)

Non-small Cell Lung Cancer (NSCLC)

United States, Australia, Belgium, Canada, Chile, France, Germany, Hungary, Italy, Japan, Korea, Republic of, Malaysia, Netherlands, Peru, Portugal, Romania, Russian Federation, Singapore, Spain, Taiwan, Thailand, Ukraine, United Kingdom
Astellas Pharma Inc

Completed

Study of Erlotinib (Tarceva®) in Combination With OSI-906 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) With Activating Mutations of the Epidermal Growth Factor Receptor (EGFR) Gene

NSCLC | Non Small Cell Lung Cancer

United States, Canada, Korea, Republic of, Singapore, Thailand, Hong Kong
AZ-VUB

Unknown

An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation

Cancers Harbouring an EGFR Mutation, (Excluding Non-squamous Non- Small Cell Lung Cancer, a Registered Indication), a HER2 Mutation or a HER3 Mutation

Belgium
University College, London
Boehringer Ingelheim

Completed

Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients (TIMELY)

Carcinoma, Non-Small-Cell Lung

United Kingdom
Yonsei University

Unknown

A Phase III, Randomized, Multi-center Study to Determine the Efficacy of the Intercalating Combination Treatment of Chemotherapy and Gefitinib or Chemotherapy as Adjuvant Treatment in NSCLC With Common EGFR Mutations.

Completely Resected NSCLC With Common EGFR Mutations

Korea, Republic of
Xinqiao Hospital of Chongqing

Terminated

Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC (CERTAIN)

Non Small Cell Lung Cancer

China
Boehringer Ingelheim

Completed

Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Carcinoma, Non-Small-Cell Lung

Serbia, Thailand, Poland, Romania, Egypt, Philippines, Malaysia
Massachusetts General Hospital
Dana-Farber Cancer Institute; Genentech, Inc.

Completed

Erlotinib in Patients With Resected, Early Stage NSCLC With Confirmed Mutations in the EGFR

Non-small Cell Lung Cancer

United States
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Non-Small Cell Lung Cancer | Brain Metastases
AstraZeneca

Withdrawn

Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong

Non-small Cell Lung Cancer
Fujian Cancer Hospital

Unknown

EGFR-TKIs Combine With Anlotinib as First-line Treatment for Patients With Advanced EGFR Mutation-positive NSCLC

EGFR Gene Mutation

China
Astellas Pharma Inc

Terminated

A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Naïve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

EGFR-TKI-naïve Patients With NSCLC Harboring EGFR Activating Mutations

Japan
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
Hoffmann-La Roche

Completed

A Study of Tarceva (Erlotinib) as First Line Therapy in Participants With Non-Small Cell Lung Cancer Harbouring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-Squamous Non-Small Cell Lung Cancer

Hong Kong, Korea, Republic of, Taiwan, Thailand
Guangdong Association of Clinical Trials
Zhejiang Cancer Hospital; Peking University People's Hospital; Sun Yat-sen University and other collaborators

Unknown

Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer (EMERGING)

Non-small Cell Lung Cancer

China
First Affiliated Hospital of Guangxi Medical University

Unknown

Anlotinib Plus Docetaxel for the Treatment of EGFR/ALK/ROS1 Mutation-negative Advanced Nonsquamous NSCLC

Non-small Cell Lung Cancer
Astellas Pharma Global Development, Inc.

Terminated

A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations

Non-small Cell Lung Cancer (NSCLC) | Epidermal Growth Factor Receptor (EGFR) Mutations

United States
Sun Yat-sen University

Unknown

Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation (ICTAN)

Lung Cancer

China
Hebei Medical University Fourth Hospital

Unknown

A Study of Apatinib Plus EGFR-TKI as First Line Treatment in Patients With Non-squamous NSCLC Harboring EGFR Mutations

NSCLC

China
Novartis Pharmaceuticals

Withdrawn

Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
National Taiwan University Hospital

Completed

AUY922 in Patient With Stage IV NSCLC (NSCLC)

Non-small Cell Lung Cancer (NSCLC)

Taiwan
National Taiwan University Hospital

Completed

Selumetinib in Combination With Gefitinib in NSCLC Patients

Non-small Cell Lung Cancer (NSCLC)

Taiwan
Guangdong Association of Clinical Trials

Unknown

Compare Bevacizumab in Combination With Erlotinib Versus Erlotinib Alone in NSCLC Patients Activating EGFR Mutations

NSCLC

China
Sun Yat-sen University

Unknown

Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in Ⅲb/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation

Lung, Carcinoma

China
Memorial Sloan Kettering Cancer Center

Completed

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Oligometastatic Lung Adenocarcinoma

United States
Sun Yat-sen University

Unknown

NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations. (NEGOTIATE)

Lung Cancer

China
Massachusetts General Hospital

Completed

Phase 2 Study of AUY922 in NSCLC Patients With Exon 20 Insertion Mutations in EGFR

Non Small Cell Lung Cancer

United States
Boehringer Ingelheim

Completed

BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation

Adenocarcinoma | Carcinoma, Non-Small-Cell Lung

Hong Kong, Canada, Korea, Republic of, Belgium, Australia, United States, Taiwan, United Kingdom, Germany, Italy, Japan, Austria, Thailand, Peru, Ireland, Russian Federation, Philippines, France, Brazil, Chile, Argentina, Hungary, M... and more
Fujian Cancer Hospital

Unknown

Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation (Geber)

Lung Adenocarcinoma | EGFR Mutation

China
First People's Hospital of Hangzhou

Completed

T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
Massachusetts General Hospital
Boehringer Ingelheim; University of Texas

Completed

Understanding Mechanisms of Acquired Resistance to BIBW2992

Non-small Cell Lung Cancer | EGFR Mutations

United States
David M. Jackman, MD
Beth Israel Deaconess Medical Center; Genentech, Inc.; Brigham and Women's Hospital

Completed

Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC

Non-small Cell Lung Cancer

United States
Qingdao Central Hospital

Completed

Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer

Progression Free Survival

China
Qingdao Central Hospital

Completed

Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)

EGFR-TKI Resistant Mutation

China
First People's Hospital of Hangzhou

Completed

EGFR Mutations on ctDNA in Patients With Advanced NSCLC

Non-small Cell Lung Cancer Stage III | Non-Small-Cell Lung Cancer Metastatic

China
AstraZeneca

Terminated

Observational Study of Patients With Locally Advanced or Metastatic NSCLC (Non-Small Cell Lung Cancer) (PANORAMA)

Carcinoma, Non-Small-Cell Lung

France, Spain, United Kingdom, China, Canada, Taiwan
David M. Jackman, MD
Massachusetts General Hospital; AstraZeneca

Completed

High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations

Non-Small Cell Lung Cancer

United States
AIO-Studien-gGmbH
AstraZeneca

Terminated

Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB (NeoIntercal)

NSCLC | Non-squamous Non-small Cell Lung Cancer Stage II | Non-squamous Non-small Cell Lung Cancer Stage IIIA | Non-squamous Non-small Cell Lung Cancer Stage IIIB | Activating EGFR Mutation

Germany
Samsung Medical Center

Unknown

The Continuation of Gefitinib Treatment Beyond Progression in Non-small Cell Lung Cancer Patients With EGFR Mutation

Non-small Cell Lung Cancer

Korea, Republic of

Search clinical trials for: EGFR C797S mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Guatemala

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations